Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Glycomine

Glycomine
2013 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$33M LATEST DEAL AMOUNT
9 INVESTORS
Description

Developer of nano medicines designed to develop a new generation of replacement therapies for rare diseases. The company's medicines include orphan drugs that combine replacement therapies such as substrates, enzymes or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians to treat their patients for serious rare monogenic disorders of metabolism and protein misfolding.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • MBC BioLabs
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Glycomine’s full profile, request a free trial.

Glycomine Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 07-Aug-2019 $33M 0000 0000 Completed Clinical Trials - General
3. Early Stage VC (Series A) 16-Nov-2016 0000 0000 000.00 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Glycomine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B-2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 1,337,056 $0.000100 $3.8 $3.8 1x $3.8 2.16%
To view this company’s complete Cap Table, request access »

Glycomine Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MiNA Therapeutics Venture Capital-Backed London, United Kingdom 00 000.00 0000000000 0 000.00
000000000 00000000 Corporation Pasadena, CA 000 00.000 0000
0000000 0000000000 Venture Capital-Backed La Jolla, CA 00000 00000000000 00000
00000000 000000000 Venture Capital-Backed Boston, MA 000 00.000 000000000 00.000
0000000 0000000000 Formerly VC-backed London, United Kingdom 00 00000 000000000 00000
To view this company’s complete list of competitors, request access »

Glycomine Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Asahi Kasei Pharma America Corporation Minority 000 0000 000000 0
Mission Bay Capital Venture Capital Minority 000 0000 000000 0
Novo Holdings Corporate Venture Capital Minority 000 0000 000000 0
Chiesi Ventures Corporate Venture Capital Minority 000 0000 000000 0
Matt Wilsey Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Glycomine Executive Team (4)

Name Title Board
Seat
Contact
Info
Peter McWilliams Ph.D Chief Executive Officer & Board Member
Matt Wilsey Advisor
Patrice Rioux MD Chief Medical Officer

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »

Glycomine Board Members (5)

Name Representing Role Since Contact
Info
Christopher Starr Ph.D Self Board Member 000 0000
Fred Middleton Sanderling Ventures Board Member 000 0000
Giacomo Chiesi Chiesi Ventures Board Member 000 0000
Kenneth Harrison Ph.D Novo Holdings Board Member 000 0000
Peter McWilliams Ph.D Glycomine Chief Executive Officer & Board Member 000 0000